ByrneDDoyleFBrannickS, et al. (2024) Evaluating the psychometric structure of the Hamilton Rating Scale for Depression pre- and post-treatment in antidepressant randomised trials: Secondary analysis of 6843 individual participants from 20 trials. Psychiatry Research339: 116057.
6.
CartwrightN (2007) Are RCTs the gold standard?BioSocieties2: 11–20.
7.
CartwrightN (2011) A philosopher’s view of the long road from RCTs to effectiveness. The Lancet377: 1400–1401.
8.
CiprianiAFurukawaTASalantiG (2018) Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. The Lancet391: 1357–1366.
9.
DahabrehIJBibbins-DomingoK (2024) Causal inference about the effects of interventions from observational studies in medical journals. JAMA331: 1845.
10.
FinbergJGillmanP (2011) Pharmacology of MAO-B inhibitors and the cheese reaction. International Review of Neurobiology100: 169–190.
11.
FlockhartDA (2012) Dietary restrictions and drug interactions with monoamine oxidase inhibitors: An update. Journal of Clinical Psychiatry73(Suppl. 1): 17–24.
12.
GillCJSabinLSchmidCH (2005) Why clinicians are natural Bayesians. BMJ330: 1080–1083.
13.
GillmanPK (2011) CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity. Journal of Psychopharmacology25: 429–433.
14.
GillmanPK (2018) A reassesment of the safety profile of monoamine oxidase inhibitors: Elucidating tired old tyramine myths. Journal of Neural Transmission (Vienna)125: 1707–1717.
15.
GillmanPKVan den EyndeV (2023) A five-pronged critique of ‘Serotonin syndome—A focused review’. Basic & Clinical Pharmacology & Toxicology133: 548–549.
16.
GoligherECHeathAHarhayMO (2024) Bayesian statistics for clinical research. The Lancet404: 1067–1076.
17.
GreenlandSSennSJRothmanKJ, et al. (2016) Statistical tests, P values, confidence intervals, and power: A guide to misinterpretations. European Journal of Epidemiology31: 337–350.
18.
HillAB (1965) The environment and disease: Association or causation?Proceedings of the Royal Society of Medicine58: 295–300.
19.
HillAB (1966) Reflections on controlled trial. Annals of the Rheumatic Diseases25: 107–113.
20.
IoannidisJP (2016) The mass production of redundant, misleading, and conflicted systematic reviews and meta-analyses. The Milbank Quarterly94: 485–514.
21.
Lopez-MunozFAlamoCJuckelG, et al. (2007) Half a century of antidepressant drugs: O n the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part I: monoamine oxidase inhibitors. Journal of Clinical Psychopharmacol27: 555–559.
22.
PearlJGlymourMJewellNP (2016) Causal Inference in Statistics: A Primer. John Wiley & Sons.
23.
PearlJMackenzieE (2018) The Book of Why: The New Science of Cause and Effect. Basic Books.
24.
RawlinsM (2008) De testimonio: On the evidence for decisions about the use of therapeutic interventions. The Lancet372: 2152–2161.
25.
RobieTR (1958) Iproniazid chemotherapy in melancholia. American Journal of Psychiatry115: 402–409.
26.
ShulmanKIFischerHDHerrmannN, et al. (2009) Current prescription patterns and safety profile of irreversible monoamine oxidase inhibitors: A population-based cohort study of older adults. Journal of Clinical Psychiatry70: 1681–1686.
27.
Van den EyndeVAbdelmoeminWRAbrahamMM, et al. (2022a) The prescriber’s guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression. CNS Spectrums28: 427–440.
28.
Van den EyndeVGillmanPKBlackwellBB (2022b) The prescriber’s guide to the MAOI diet-thinking through tyramine troubles. Psychopharmacology Bulletin52: 73–116.
